Oligometastatic Prostate Cancer: A Comparison between Multimodality Treatment vs. Androgen Deprivation Therapy Alone.
Francesco Alessandro MistrettaStefano LuzzagoAndrea ContiElena VerriGiulia MarvasoClaudia Collà RuvoloMichele CatellaniEttore Di TrapaniGabriele CozziRoberto BianchiMatteo FerroGiovanni CordimaAntonio BresciaMaria Cossu RoccaVincenzo MironeBarbara A Jereczek-FossaFranco NolèOttavio de CobelliGennaro MusiPublished in: Cancers (2022)
MMT was associated with lower CSM, mCRPC, and second-line therapy rates. A lower rate of treatment-related adverse events was recorded for the MMT group.